A Bioinformatics Analysis of FAM3A to Identify its Potential Role as a Biomarker in Liver Hepatocellular Cancer

Abstract

Liver hepatocellular cancer (LIHC) is positioned as the third cancer with the highest mortalities worldwide, and high mortalities are associated with late diagnosis and recurrence. This study advances bioinformatics analysis of FAM3A expression in LIHC to evaluate its potential as a prognostic, diagnostic and therapeutic biomarker. Bioinformatics tools such as UALCAN, GEPIA2, KM plotter, TIMER2 and cBioPortal are employed to conduct analysis. Initially, the expression analysis revealed up-regulation of FAM3A in LIHC based on various variables. Further, the study observed that FAM3A methylation regulates expression as variation in methylation level of FAM3A was assessed in LIHC. Moreover, this over-expression of FAM3A results in poor overall survival (OS) in LIHC patients. All of these proposed that FAM3A has a role in the progression and development of LIHC. While examined association of FAM3A expression and infiltration level of CD8+ T cells in LIHC patients using TIMER2 revealed that FAM3A has a positive correlation with purity in LIHC that highlights the molecular landscape. Analysis of genetic alteration revealed minute role of FAM3A in LIHC still provides valuable insight. Overall, our findings reveal that FAM3A has potential as diagnostic, therapeutic and prognostic biomarkers in LIHC.